Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions
ARQT Stock Forecast
Arcutis Biotherapeutics stock forecast is as follows: an average price target of $31.00 (represents a 198.94% upside from ARQT’s last price of $10.37) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ARQT Price Target
The average price target for Arcutis Biotherapeutics (ARQT) is $31.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $18.00. This represents a potential 198.94% upside from ARQT's last price of $10.37.
ARQT Analyst Ratings
According to 4 Wall Street analysts, Arcutis Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ARQT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 0 'Hold' (0.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Arcutis Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Serge Belanger | Needham | $18.00 | $8.13 | 121.40% | 73.58% |
| May 15, 2024 | Uy Ear | Mizuho Securities | $18.00 | $8.13 | 121.40% | 73.58% |
| Jan 02, 2024 | - | Mizuho Securities | $8.00 | $3.43 | 133.24% | -22.85% |
| Dec 13, 2022 | - | Morgan Stanley | $51.00 | $16.58 | 207.60% | 391.80% |
| Apr 27, 2022 | Eric Cha | Goldman Sachs | $37.00 | $19.61 | 88.63% | 256.80% |
The latest Arcutis Biotherapeutics stock forecast, released on May 15, 2024 by Serge Belanger from Needham, set a price target of $18.00, which represents a 121.40% increase from the stock price at the time of the forecast ($8.13), and a 73.58% increase from ARQT last price ($10.37).
Arcutis Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $14.67 |
| Last Closing Price | $10.37 | $10.37 | $10.37 |
| Upside/Downside | -100.00% | -100.00% | 41.47% |
In the current month, the average price target of Arcutis Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcutis Biotherapeutics's last price of $10.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Needham | Buy | Buy | Hold |
| Aug 28, 2024 | Jefferies | Underperform | Underperform | Hold |
| Aug 28, 2024 | Jefferies | - | Buy | Initialise |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 10, 2024 | Needham | Buy | Buy | Hold |
| May 15, 2024 | Needham | Buy | Buy | Hold |
| Apr 12, 2024 | Needham | Buy | Buy | Hold |
| Apr 12, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
| Dec 13, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
Arcutis Biotherapeutics's last stock rating was published by Needham on Aug 28, 2024. The company gave ARQT a "Buy" rating, the same as its previous rate.
Arcutis Biotherapeutics Financial Forecast
Arcutis Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $13.53M | $38.11M | $5.19M | $2.78M | $2.96M | $725.00K |
| Avg Forecast | $71.00M | $71.00M | $63.00M | $55.00M | $46.71M | $36.82M | $29.09M | $15.18M | $11.41M | $32.91M | $4.60M | $3.14M | $2.20M | $614.29K |
| High Forecast | $75.29M | $75.29M | $66.81M | $58.33M | $49.53M | $38.63M | $30.85M | $16.09M | $12.10M | $34.91M | $4.88M | $3.33M | $2.34M | $651.44K |
| Low Forecast | $68.75M | $68.75M | $61.00M | $53.25M | $45.23M | $34.99M | $28.17M | $14.69M | $11.05M | $31.87M | $4.45M | $3.04M | $2.13M | $594.79K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.19% | 1.16% | 1.13% | 0.89% | 1.34% | 1.18% |
Arcutis Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $15.18M, with a low forecast of $14.69M, and a high forecast of $16.09M. ARQT's average Quarter revenue forecast represents a 12.19% increase compared to the company's last Quarter revenue of $13.53M (Dec 23).
Arcutis Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-60.78M | $-34.18M | $-66.76M | $-73.06M | $-65.10M | $-102.53M |
| Avg Forecast | $14.20M | $14.20M | $12.60M | $11.00M | $9.34M | $7.36M | $5.82M | $3.03M | $2.28M | $6.58M | $919.68K | $627.50K | $440.50K | $122.86K |
| High Forecast | $15.06M | $15.06M | $13.36M | $11.67M | $9.91M | $7.73M | $6.17M | $3.22M | $2.42M | $6.98M | $975.31K | $665.45K | $467.14K | $130.29K |
| Low Forecast | $13.75M | $13.75M | $12.20M | $10.65M | $9.05M | $7.00M | $5.63M | $2.94M | $2.21M | $6.37M | $890.50K | $607.59K | $426.52K | $118.96K |
| Surprise % | - | - | - | - | - | - | - | - | -26.64% | -5.19% | -72.59% | -116.43% | -147.80% | -834.53% |
undefined analysts predict ARQT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arcutis Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Arcutis Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-66.28M | $-44.77M | $-70.99M | $-79.74M | $-75.61M | $-110.67M |
| Avg Forecast | $-43.22M | $-30.87M | $-30.87M | $-37.04M | $-44.41M | $-51.16M | $-63.78M | $-84.58M | $-96.58M | $-112.83M | $-154.37M | $-158.63M | $-175.75M | $-175.14M |
| High Forecast | $-41.44M | $-29.60M | $-29.60M | $-35.52M | $-42.58M | $-49.88M | $-61.14M | $-81.09M | $-71.32M | $-108.18M | $-148.00M | $-152.09M | $-168.50M | $-167.91M |
| Low Forecast | $-46.62M | $-33.30M | $-33.30M | $-39.96M | $-47.90M | $-53.71M | $-68.79M | $-91.24M | $-120.35M | $-121.70M | $-166.50M | $-171.10M | $-189.57M | $-188.91M |
| Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.40% | 0.46% | 0.50% | 0.43% | 0.63% |
Arcutis Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ARQT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Arcutis Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $48.48M | $47.59M | $45.96M | $42.92M | $37.02M | $35.47M |
| Avg Forecast | $556.91M | $556.91M | $494.16M | $431.41M | $366.36M | $288.78M | $228.17M | $119.03M | $89.48M | $258.17M | $36.07M | $24.61M | $17.28M | $4.82M |
| High Forecast | $590.59M | $590.59M | $524.05M | $457.50M | $388.52M | $303.03M | $241.97M | $126.23M | $94.89M | $273.79M | $38.25M | $26.10M | $18.32M | $5.11M |
| Low Forecast | $539.24M | $539.24M | $478.48M | $417.72M | $354.74M | $274.46M | $220.93M | $115.25M | $86.64M | $249.98M | $34.92M | $23.83M | $16.73M | $4.67M |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.18% | 1.27% | 1.74% | 2.14% | 7.36% |
Arcutis Biotherapeutics's average Quarter SG&A projection for Mar 24 is $119.03M, based on 1 Wall Street analysts, with a range of $115.25M to $126.23M. The forecast indicates a 145.54% rise compared to ARQT last annual SG&A of $48.48M (Dec 23).
Arcutis Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.72 | $-0.73 | $-1.16 | $-1.30 | $-1.24 | $-1.94 |
| Avg Forecast | $-0.35 | $-0.25 | $-0.25 | $-0.30 | $-0.36 | $-0.41 | $-0.52 | $-0.69 | $-0.78 | $-0.91 | $-1.25 | $-1.28 | $-1.42 | $-1.42 |
| High Forecast | $-0.34 | $-0.24 | $-0.24 | $-0.29 | $-0.34 | $-0.40 | $-0.50 | $-0.66 | $-0.58 | $-0.88 | $-1.20 | $-1.23 | $-1.36 | $-1.36 |
| Low Forecast | $-0.38 | $-0.27 | $-0.27 | $-0.32 | $-0.39 | $-0.43 | $-0.56 | $-0.74 | $-0.97 | $-0.99 | $-1.35 | $-1.39 | $-1.54 | $-1.53 |
| Surprise % | - | - | - | - | - | - | - | - | 0.92% | 0.80% | 0.93% | 1.01% | 0.87% | 1.37% |
According to undefined Wall Street analysts, Arcutis Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ARQT previous annual EPS of $NaN (undefined).
Arcutis Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CHRS | Coherus BioSciences | $1.04 | $9.00 | 765.38% | Hold |
| SPRO | Spero Therapeutics | $1.33 | $10.00 | 651.88% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.37 | $31.00 | 198.94% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.48 | $7.00 | 182.26% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.76 | $38.80 | 181.98% | Buy |
| INZY | Inozyme Pharma | $5.83 | $14.67 | 151.63% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| APLS | Apellis Pharmaceuticals | $35.53 | $75.38 | 112.16% | Buy |
| DSGN | Design Therapeutics | $5.77 | $9.67 | 67.59% | Buy |
| BOLT | Bolt Biotherapeutics | $0.63 | $1.00 | 58.73% | Hold |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| MIRM | Mirum Pharmaceuticals | $40.29 | $54.50 | 35.27% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.92 | $3.33 | 14.04% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
ARQT Forecast FAQ
Is Arcutis Biotherapeutics a good buy?
Yes, according to 4 Wall Street analysts, Arcutis Biotherapeutics (ARQT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of ARQT's total ratings.
What is ARQT's price target?
Arcutis Biotherapeutics (ARQT) average price target is $31 with a range of $18 to $51, implying a 198.94% from its last price of $10.37. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Arcutis Biotherapeutics stock go up soon?
According to Wall Street analysts' prediction for ARQT stock, the company can go up by 198.94% (from the last price of $10.37 to the average price target of $31), up by 391.80% based on the highest stock price target, and up by 73.58% based on the lowest stock price target.
Can Arcutis Biotherapeutics stock reach $20?
ARQT's average twelve months analyst stock price target of $31 supports the claim that Arcutis Biotherapeutics can reach $20 in the near future.
What are Arcutis Biotherapeutics's analysts' financial forecasts?
Arcutis Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $127.79M (high $135.11M, low $123.08M), average EBITDA is $25.56M (high $27.02M, low $24.62M), average net income is $-244M (high $-235M, low $-262M), average SG&A $1B (high $1.06B, low $965.38M), and average EPS is $-1.975 (high $-1.901, low $-2.119). ARQT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $260M (high $275.73M, low $251.75M), average EBITDA is $52M (high $55.15M, low $50.35M), average net income is $-142M (high $-136M, low $-153M), average SG&A $2.04B (high $2.16B, low $1.97B), and average EPS is $-1.15 (high $-1.103, low $-1.24).
Did the ARQT's actual financial results beat the analysts' financial forecasts?
Based on Arcutis Biotherapeutics's last annual report (Dec 2023), the company's revenue was $59.61M, beating the average analysts forecast of $52.06M by 14.50%. Apple's EBITDA was $-241M, missing the average prediction of $10.41M by -2415.68%. The company's net income was $-262M, missing the average estimation of $-522M by -49.82%. Apple's SG&A was $185.14M, missing the average forecast of $408.33M by -54.66%. Lastly, the company's EPS was $-0.0038, missing the average prediction of $-4.231 by -99.91%. In terms of the last quarterly report (Dec 2023), Arcutis Biotherapeutics's revenue was $13.53M, beating the average analysts' forecast of $11.41M by 18.57%. The company's EBITDA was $-60.784M, missing the average prediction of $2.28M by -2764.08%. Arcutis Biotherapeutics's net income was $-66.284M, missing the average estimation of $-96.579M by -31.37%. The company's SG&A was $48.48M, missing the average forecast of $89.48M by -45.83%. Lastly, the company's EPS was $-0.72, missing the average prediction of $-0.782 by -7.94%